0 17 Immunosuppression immunosuppression NN 18 20 by by IN 21 36 glucocorticoids glucocorticoid NNS 36 37 : : : 38 48 inhibition inhibition NN 49 51 of of IN 52 60 NF-kappa NF-kappa NNP 61 62 B B NNP 63 71 activity activity NN 72 79 through through IN 80 89 induction induction NN 90 92 of of IN 93 94 I i NN 95 100 kappa kappa NN 101 102 B B NNP 103 112 synthesis synthesis NN 113 114 [ [ ( 114 117 see see VB 118 126 comments comment NNS 126 127 ] ] ) 129 144 Glucocorticoids glucocorticoid NNS 145 148 are be VBP 149 154 among among IN 155 158 the the DT 159 163 most most RBS 164 170 potent potent JJ 171 188 anti-inflammatory anti-inflammatory JJ 189 192 and and CC 193 210 immunosuppressive immunosuppressive JJ 211 217 agents agent NNS 217 218 . . . 219 223 They they PRP 224 231 inhibit inhibit VBP 232 241 synthesis synthesis NN 242 244 of of IN 245 251 almost almost RB 252 255 all all DT 256 261 known know VBN 262 271 cytokines cytokine NNS 272 275 and and CC 276 278 of of IN 279 286 several several JJ 287 291 cell cell NN 292 299 surface surface NN 300 309 molecules molecule NNS 310 318 required require VBN 319 322 for for IN 323 329 immune immune JJ 330 338 function function NN 338 339 , , , 340 343 but but CC 344 347 the the DT 348 357 mechanism mechanism NN 358 368 underlying underlie VBG 369 373 this this DT 374 382 activity activity NN 383 386 has have VBZ 387 391 been be VBN 392 399 unclear unclear JJ 399 400 . . . 401 405 Here here RB 406 408 it it PRP 409 411 is be VBZ 412 417 shown show VBN 418 422 that that IN 423 438 glucocorticoids glucocorticoid NNS 439 442 are be VBP 443 449 potent potent JJ 450 460 inhibitors inhibitor NNS 461 463 of of IN 464 471 nuclear nuclear JJ 472 478 factor factor NN 479 484 kappa kappa NN 485 486 B B NNP 487 488 ( ( ( 488 496 NF-kappa NF-kappa NNP 497 498 B B NNP 498 499 ) ) ) 500 510 activation activation NN 511 513 in in IN 514 518 mice mouse NNS 519 522 and and CC 523 531 cultured culture VBN 532 537 cells cell NNS 537 538 . . . 539 543 This this DT 544 554 inhibition inhibition NN 555 557 is be VBZ 558 566 mediated mediate VBN 567 569 by by IN 570 579 induction induction NN 580 582 of of IN 583 586 the the DT 587 588 I i NN 589 594 kappa kappa NN 595 596 B B NNP 597 602 alpha alpha NN 603 613 inhibitory inhibitory JJ 614 621 protein protein NN 621 622 , , , 623 628 which which WDT 629 634 traps trap VBZ 635 644 activated activate VBN 645 653 NF-kappa NF-kappa NNP 654 655 B B NNP 656 658 in in IN 659 667 inactive inactive JJ 668 679 cytoplasmic cytoplasmic JJ 680 689 complexes complex NNS 689 690 . . . 691 698 Because because IN 699 707 NF-kappa NF-kappa NNP 708 709 B B NNP 710 719 activates activate VBZ 720 724 many many JJ 725 741 immunoregulatory immunoregulatory JJ 742 747 genes gene NNS 748 750 in in IN 751 759 response response NN 760 762 to to TO 763 779 pro-inflammatory pro-inflammatory JJ 780 787 stimuli stimulus NNS 787 788 , , , 789 792 the the DT 793 803 inhibition inhibition NN 804 806 of of IN 807 810 its its PRP$ 811 819 activity activity NN 820 823 can can MD 824 826 be be VB 827 828 a a DT 829 834 major major JJ 835 844 component component NN 845 847 of of IN 848 851 the the DT 852 869 anti-inflammatory anti-inflammatory JJ 870 878 activity activity NN 879 881 of of IN 882 897 glucocorticoids glucocorticoid NNS 897 898 . . .